Elderly Representation In Clinical Trials: Not A Gray Area
Source: INC Research/inVentiv Health
By Simonetta Alvino, M.D., Senior Medical Director, INC Research/inVentiv Health
Typically, clinical trials conducted in adult populations include patients between the ages of 18 and 65. This is a broad range, but arguably no longer broad enough. In most therapeutic categories, this upper age cutoff is too low, given that:
- Trial participants should be representative of the patient population receiving the therapy in daily medical practice.
- People over age 65 make up the majority of patients for many medications treating chronic conditions.
- The over-65 segment is the fastest growing segment of the world's population. By 2050, the number of people ages 65+ will be 16 percent of the global total, up from 5 percent in 1950
Regulators have, in fact, offered guidance on the subject, stating that study participants should be representative of the patient population and that protocols should not set an arbitrary upper age limit.
VIEW THE WHITE PAPER!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more